Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Vinita Akula ^{[1
]}

Lily Chen ^{[1
]}

Yusuf Acikgoz ^{[2
]}

Katherine Klein ^{[1
]}

Betul Gok Yavuz ^{[3
]}

Lokman Cevik ^{[4
]}

Tarik Demir ^{[5
]}

Ashish Manne ^{[2
]}

Ilyas Sahin ^{[6
]}

Ahmed Kaseb ^{[7
]}

Elshad Hasanov ^{[2
]}

机构：

[1] The University of Texas Health Science Center at Houston (UTHealth),Department of Internal Medicine

[2] The Ohio State University Comprehensive Cancer Center,Division of Medical Oncology, Department of Internal Medicine

[3] University of Missouri,Department of Medicine

[4] The Ohio State University Wexner Medical Center,Department of Pathology

[5] Northwestern University,Division of Hematology and Oncology Developmental Therapeutics Institute

[6] University of Florida,Division of Hematology & Oncology, Department of Medicine

[7] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal Medical Oncology

来源：

npj Precision Oncology | / 9卷 / 1期

关键词：

D O I：

10.1038/s41698-025-00846-4

中图分类号：

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

共 50 条

[21] Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
Nishida, Naoshi
Kudo, Masatoshi
CANCERS, 2020, 12 (05)
[22] Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, Ran
Jin, Tianqiang
Xu, Feng
FRONTIERS IN IMMUNOLOGY, 2023, 14
[23] Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Cui, Xiaowen
Ruan, Minghao
Li, Yao
Yang, Cheng
Zhou, Liuyu
Zhang, Jin
Jin, Riming
Wu, Dong
Wang, Ruoyu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Liu, Tong
Meng, Guorui
Ma, Shihui
You, Junqi
Yu, Liang
He, Risheng
Zhao, Xudong
Cui, Yunfu
FRONTIERS IN IMMUNOLOGY, 2024, 15
[25] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
Zeng, Zhu
Yang, Biao
Liao, Zheng-Yin
ONCOLOGY LETTERS, 2020, 20 (04)
[26] Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
Cui, Tian-ming
Liu, Yao
Wang, Jia-bei
Liu, Lian-xin
ONCOTARGETS AND THERAPY, 2020, 13 : 11725 - 11740
[27] Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
Chen, Xiu
Kou, Liqiu
Xie, Xiaolu
Su, Song
Li, Jun
Li, Yaling
IMMUNOLOGY, 2024, 172 (01) : 21 - 45
[28] Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, Bruno
Chan, Stephen L.
Meyer, Tim
Reig, Maria
El-Khoueiry, Anthony
Galle, Peter R.
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 320 - 341
[29] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
Liu, Hao-Tian
Jiang, Meng-Jie
Deng, Zhu-Jian
Li, Le
Huang, Jian-Li
Liu, Zhen-Xiu
Li, Le-Qun
Zhong, Jian-Hong
FRONTIERS IN ONCOLOGY, 2021, 11
[30] Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
Personeni, Nicola
Pressiani, Tiziana
D'Alessio, Antonio
Prete, Maria Giuseppina
Bozzarelli, Silvia
Terracciano, Luigi
Dal Buono, Arianna
Capogreco, Antonio
Aghemo, Alessio
Lleo, Ana
Lutman, Romano Fabio
Roncalli, Massimo
Giordano, Laura
Santoro, Armando
Di Tommaso, Luca
Rimassa, Lorenza
CANCERS, 2021, 13 (22)

← 1 2 3 4 5 →